

Contact

EURADIA e.V. is a Non-Profit-Association, registered at the County Court Düsseldorf, Registry Number: VR 9885 (Rheindorfer Weg 3, 40591 Düsseldorf, Germany)

Executive Committee

Prof Philippe A. Halban, Chair
Dr Laurent Vaur, Vice-Chair
Dr Philip Ambery, Treasurer
Ms Sylvia Lion, Member
Ms Anne-Marie Felton, Member

Staff

Sarah Hills, Executive Director (Sarah.Hills@euradia.org)
Regina Sautter, Administrator (Regina.Sautter@euradia.org)

www.EURADIA.org

A resource for researchers and healthcare professionals conducting basic or clinical research in the field of diabetes. The website provides information from EURADIA on research issues such as:

- **DIAMAP Report and Databases**
- **EURADIA activities**
- **Calls for grant applications**
- **Framework Programme projects**
- **Quarterly Newsletter**
- **News from the European Union**
- **Position Statements**
- **Links to online journals**

To date, EURADIA is proud to feature the following non-profit organisations and leading pharmaceutical companies among its members:

EURADIA Partners

European Association for the Study of Diabetes (EASD)

Foundation of European Nurses in Diabetes (FEND)

International Diabetes Federation European Region (IDF Europe)

International Society for Pediatric and Adolescent Diabetes (ISPAD)

Juvenile Diabetes Research Foundation International (JDRF)

Primary Care Diabetes Europe (PCDE)

AstraZeneca

Bayer Healthcare

Eli Lilly and Company

GlaxoSmithKline

Merck Sharp & Dohme (MSD)

Novartis

Novo Nordisk

Roche

Sanofi Aventis

Advocacy for Diabetes Research in Europe

As a unique alliance of NGOs and pharmaceutical companies, EURADIA's mission is to improve the lives of people affected by diabetes both now and in the future, through advocacy of diabetes research in Europe at the highest political and societal levels of influence, and by shaping the allocation of resources for diabetes research in Europe through increased awareness.

September 2011

Alarm about funding for diabetes research in Europe

Diabetes is a major epidemic: more than 30 million Europeans (EU 27) have the condition, a figure expected to increase sharply by 2025. There is a dramatic rise in both type 1 and type 2 diabetes, especially in younger people.

Indirect costs (costs of lost production) may be as much as **five times those of the direct costs**, which already **represent more than 10% of total health expenditures** in most EU Member States.

Diabetes is highly ranked among the leading single causes of death, but the actual number of deaths for which diabetes was an undocumented contributing factor is several times higher.

Diabetes research in Europe is under-funded relative to the potential of its researchers and its importance to society. Support for diabetes research from the European Commission has seen a welcome increase during the 6th and 7th Research Framework Programmes, but spending on diabetes research in Europe is much lower than in the United States despite similar expertise and opportunity.

There is an urgent need for much greater investment in research in order to find a cure for diabetes and its complications. EURADIA's aim is to increase public and private funding for diabetes research in Europe and to ensure that such research is well coordinated.

The figures!

	European Union
Prevalence	>30 million approx. 8.6% of the population ¹ (2006 IDF Diabetes Atlas)
Mortality	6 th leading cause ² (2006 Eurostat)
Direct costs	€50 billion ³ (2005 IDF/FEND)
Research funding	€500 million ⁴ (2008 DIAMAP)

¹Between 20 and 79 years; ²13.9 per 100 000 of the population; ³average per year, *Diabetes: The Policy Puzzle*; ⁴European Commission, national government and non-profit organisation funding for diabetes research in 2008 (best estimate, *DIAMAP Road Map Report* September 2010)

European Commission, Eurostat: Statistical Office of the European Communities, FEND: Federation of European Nurses in Diabetes, IDF: International Diabetes Federation, (See 'Links' for sources of information on www.EURADIA.org.)

DIAMAP Road Map for Diabetes Research in Europe

The aim of DIAMAP, a project funded by the European Commission (FP7-HEALTH-200701), was to chart the future of diabetes research in Europe for the benefit of the person with diabetes.

In support of this innovative mission a survey was carried out of European diabetes research, and a strategic road mapping exercise for diabetes research in Europe was undertaken.

The DIAMAP report, comprising strategic maps and reports from seven sub-groups, is intended to guide investment in diabetes research in Europe for the period 2010-2019 and to suggest means for improved coordination. The two public DIAMAP databases provide insight into the current landscape of European diabetes research and its' funding.

DIAMAP presents the first **strategic plan for European diabetes research**, for the benefit of all individuals with the condition.

The DIAMAP strategic road map report and research and funding databases are now available from:

www.DIAMAP.eu